William Blair Keeps a Buy Rating on Adamas Pharmaceuticals (ADMS)

William Blair analyst Tim Lugo maintained a Buy rating on Adamas Pharmaceuticals (ADMSResearch Report) on June 3. The company’s shares closed last Wednesday at $5.12.

According to TipRanks.com, Lugo is a 5-star analyst with an average return of 16.5% and a 48.5% success rate. Lugo covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Collegium Pharmaceutical, and VistaGen Therapeutics.

Currently, the analyst consensus on Adamas Pharmaceuticals is a Strong Buy with an average price target of $9.50, representing a 91.9% upside. In a report issued on June 7, H.C. Wainwright also reiterated a Buy rating on the stock with a $10.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $9.15 and a one-year low of $2.43. Currently, Adamas Pharmaceuticals has an average volume of 342.7K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer’s disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.